Skip to main content
Print Save

Tralokinumab Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 12, 2023.

Applies to tralokinumab: subcutaneous solution.

Serious side effects of Tralokinumab

Along with its needed effects, tralokinumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tralokinumab:

More common

  • Body aches or pain
  • burning, dry, or itching eyes
  • chills
  • cough
  • discharge, excessive tearing
  • ear congestion
  • fever
  • headache
  • loss of voice
  • redness, pain, swelling of the eye, eyelid, or inner lining of eyelid
  • stuffy or runny nose
  • trouble breathing
  • unusual tiredness or weakness

Less common

  • Black, tarry stools
  • chest pain
  • painful or difficult urination
  • sore throat
  • sores, ulcers, or white spots on lips or in mouth
  • swollen glands
  • unusual bleeding or bruising

Incidence not known

  • Chest tightness
  • difficulty swallowing
  • dizziness
  • fast heartbeat
  • hives, itching, skin rash
  • large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue

Other side effects of Tralokinumab

Some side effects of tralokinumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to tralokinumab: subcutaneous solution.

Respiratory

Very common (10% or more): Upper respiratory tract infections (included upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis, nasopharyngitis, common cold; up to 30%)[Ref]

Ocular

Very common (10% or more): Conjunctivitis (included conjunctivitis, allergic conjunctivitis; up to 13.6%)

Common (1% to 10%): Allergic conjunctivitis

Uncommon (0.1% to 1%): Keratitis (including keratoconjunctivitis, atopic keratoconjunctivitis, ulcerative keratitis)

Immunologic

Common (1% to 10%): Anti-drug antibody

Uncommon (0.1% to 1%): Neutralizing antibodies

Hematologic

Common (1% to 10%): Eosinophilia (included eosinophilia, increased eosinophil count)

Dermatologic

Uncommon (0.1% to 1%): Eczema herpeticum[Ref]

Local

Very common (10% or more): Injection site reactions (included pain, swelling, erythema/redness; up to 11.1%)[Ref]

Frequently asked questions

References

1. Product Information. Adbry (tralokinumab). Leo Pharma Inc. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer